# Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction

> **NCT06619600** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hospital Clinic of Barcelona** · enrollment: 54 (actual)

## Conditions studied

- ST-segment Elevation Myocardial Infarction (STEMI)
- Diabetes Mellitus
- Heart Failure
- Myocardial Fibrosis

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06619600
- **Lead sponsor:** Hospital Clinic of Barcelona
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-30
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06619600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06619600, "Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06619600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*